Correspondence 0001213900-22-079148 from InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc.
Date: Dec. 12, 2022 · CIK: 0001728328 · Accession: 0001213900-22-079148
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268700
Letter
INMED PHARMACEUTICALS INC.
Suite 310 - 815 West Hastings Street
Vancouver, British Columbia, Canada
V6C 1B4
VIA EDGAR
December 12, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc.
Acceleration Request for Registration Statement on Form S-1
Filed December 7, 2022
File No. 333-268700
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to December 14, 2022, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Brian Fenske of Norton Rose Fulbright US LLP at (713) 651 5557.
Sincerely,
INMED PHARMACEUTICALS INC.
Show Raw Text
CORRESP
1
filename1.htm
INMED PHARMACEUTICALS INC.
Suite 310 - 815 West Hastings Street
Vancouver, British Columbia, Canada
V6C 1B4
VIA EDGAR
December 12, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc.
Acceleration Request for Registration Statement on Form S-1
Filed December 7, 2022
File No. 333-268700
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended,
InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated
to December 14, 2022, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Brian
Fenske of Norton Rose Fulbright US LLP at (713) 651 5557.
Sincerely,
INMED PHARMACEUTICALS INC.
/s/ Eric A. Adams
Eric A. Adams
President and Chief Executive Officer
cc: Sarah Li, InMed Pharmaceuticals Inc.
Brian Fenske, Norton Rose Fulbright US LLP